Quell Therapeutics
Summary
In a significant market movement during November 2021, Quell Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £117,017,985. Leading the round was Point72 Ventures, Tekla Capital Management, Jeito Capital, SV Health Investors, Janus Henderson Investors, British Patient Capital, Fidelity Management & Research Company LLC, Monashee Investment Management LLC, Syncona Partners, Ridgeback Capital Investments.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Point72 Ventures
Lead Investor / Acquirer
Tekla Capital Management
Lead Investor / Acquirer
Jeito Capital
Lead Investor / Acquirer
SV Health Investors
Lead Investor / Acquirer
Janus Henderson Investors
Lead Investor / Acquirer
British Patient Capital
Lead Investor / Acquirer
Fidelity Management
Lead Investor / Acquirer
Research Company LLC
Lead Investor / Acquirer
Monashee Investment Management LLC
Lead Investor / Acquirer
Syncona Partners
Lead Investor / Acquirer
Ridgeback Capital Investments
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series B prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in